meningitis/ventriculitis secondary to N. meningitidis, H. influenzae, S. pneumoniaeAlthough cefotaxime has demonstrated efficacy in these infections, it is not necessarily considered to be the first-line agent. In meningitis, cefotaxime crosses the blood–brain barrier better than cefuroxime. Spectrum of activity
As a β-lactam antibiotic in the third-generation class of cephalosporins, cefotaxime is active against numerous Gram-positive and Gram-negative bacteria, including several with resistance to classic β-lactams such as penicillin. These bacteria often manifest as infections of the lower respiratory tract, skin, central nervous system, bone, and intra-abdominal cavity. While regional susceptibilities must always be considered, cefotaxime typically is effective against these organisms (in addition to many others):
Staphylococcus aureus (not including MRSA) and S. epidermidis
Streptococcus pneumoniae and S. pyogenes
Escherichia coli
Haemophilus influenzae
Neisseria gonorrhoeae and N. meningitidis
Klebsiella spp. Burkholderia cepacia
Proteus mirabilis and P. vulgaris
Enterobacter spp. Bacteroides spp. Fusobacterium spp.Notable organisms against which cefotaxime is not active include Pseudomonas and Enterococcus. As listed, it has modest activity against the anaerobic Bacteroides fragilis. The following represents MIC susceptibility data for a few medically significant microorganisms:

H. influenzae: ≤0.007 – 0.5 µg/mL
S. aureus: 0.781 – 172 µg/mL
S. pneumoniae: ≤0.007 – 8 µg/mLHistorically, cefotaxime has been considered to be comparable to ceftriaxone (another third-generation cephalosporin) in safety and efficacy for the treatment of bacterial meningitis, lower respiratory tract infections, skin and soft tissue infections, genitourinary tract infections, and bloodstream infections, as well as prophylaxis for abdominal surgery. The majority of these infections are caused by organisms traditionally sensitive to both cephalosporins.
Brain fag syndrome (BFS) describes a set of symptoms; somatic, sleep-related and cognitive complaints, difficulty in concentrating and retaining information, head and or neck pains, and eye pain. Brain Fag is very common in adolescents and young adults. It is believed to be the most common in these age ranges due to the immense amount of pressure occurring in life during these years. The condition was arguably first described in Nigerian high school and university students in the 1960s. It is considered a culture-bound syndrome caused by excessive pressure to be successful among the young. Etymology
The term brain fag presumably stems from the verb meaning of the word, "To cause (a person, animal, or part of the body) to become tired; to fatigue, wear out" chiefly found in British English. Classification
BFS is classified in the fourth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) as a culture-bound syndrome. Individuals with symptoms of brain fag must be differentiated from those with the syndrome according to the Brain Fag Syndrome Scale (BFSS); Ola et al said it would not be "surpris[ing] if BFS was called an equivalent of either depression or anxiety". Causes
Brain Fag is typically driven in people with high anxiety and people with high stress levels. Morakinyo found in 20 people with BFS an achievement drive that was anxiety-related that led to the use of psychostimulants and consequent sleep deprivation which contributed to cognitive disruption. Omoluabi related BFS to test anxiety.